Literature DB >> 3611771

Pulse pressure in sustained essential hypertension: a haemodynamic study.

M E Safar, S St Laurent, A L Safavian, B M Pannier, G M London.   

Abstract

Central and forearm haemodynamics were studied in 73 middle-aged male subjects: 14 normotensive controls and 59 patients with sustained essential systolic/diastolic hypertension. Hypertensives were divided into two groups: pulse pressure within the normal range (40-60 mmHg; group I) or above 60 mmHg (group II) for the same level of mean arterial pressure (MAP). Indices of systemic and forearm arterial compliance and distensibility for the same age and MAP were reduced to the same extent in group I and II. In contrast, the peak systolic blood flow velocity of the brachial artery, cardiac output (CO) and stroke volume (SV) were significantly greater in group II than in group I. Systemic and forearm vascular resistances were significantly increased in group I but remained within the normal range in group II. The study provided evidence that, in middle age, there is a group of hypertensive patients characterized by a disproportionate increase in pulse pressure for the level of MAP. The elevation of the pulsed component of blood pressure (BP) reflects a relative hyperkinesia with an increase in CO and arteriolar vasodilatation. The subsequent increase in systolic pressure is produced by a combination of reduced arterial distensibility and increased SV.

Entities:  

Mesh:

Year:  1987        PMID: 3611771     DOI: 10.1097/00004872-198704000-00013

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  2 in total

1.  Height and cognition at work: Labor market productivity in a low income setting.

Authors:  Daniel LaFave; Duncan Thomas
Journal:  Econ Hum Biol       Date:  2016-11-05       Impact factor: 2.184

2.  Primary stroke prevention and hypertension treatment: which is the first-line strategy?

Authors:  Roberta Ravenni; Joe F Jabre; Edoardo Casiglia; Alberto Mazza
Journal:  Neurol Int       Date:  2011-09-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.